Latest News & Features
Americas
Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company. 22 July 2025
Americas
Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026. 21 July 2025
Americas
This LSPN session features experts from EIP, The Broad Institute of MIT and Harvard, Pfizer, and an independent specialist discussing the protection of life science innovations involving big data, AI, and machine learning. 21 July 2025
Europe
Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’. 18 July 2025
Americas
Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN. 18 July 2025
Europe
Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency. 17 July 2025
Careers
Three of the new shareholders have IP and life sciences expertise, bringing a commercial and policy focus to the firm. 17 July 2025
Americas
Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents. 16 July 2025
Americas
LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines. 16 July 2025
Europe
After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more. 15 July 2025